Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 More Search Options

Search Results (1969)

Click the Why column to see why an item matched the search.

MatchTypeWhy
Van Rhee, FritsPerson Why?
Zangari, MaurizioPerson Why?
Schinke, CarolinaPerson Why?
Zhan, FenghuangPerson Why?
Al Hadidi, SamerPerson Why?
Tricot, GuidoPerson Why?
Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.Academic Article Why?
Thanendrarajan, SharmilanPerson Why?
Yaccoby, ShmuelPerson Why?
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.Academic Article Why?
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.Academic Article Why?
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.Academic Article Why?
A pooled analysis of alcohol consumption and risk of multiple myeloma in the international multiple myeloma consortium.Academic Article Why?
A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium.Academic Article Why?
Delgado-Calle, JesusPerson Why?
A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium.Academic Article Why?
Smoldering multiple myeloma.Academic Article Why?
The use of bone-modifying agents in multiple myeloma.Academic Article Why?
Young Adult and Usual Adult Body Mass Index and Multiple Myeloma Risk: A Pooled Analysis in the International Multiple Myeloma Consortium (IMMC).Academic Article Why?
[Myeloma cancer stem cells:the new target for multiple myeloma].Academic Article Why?
A gene signature can predict risk of MGUS progressing to multiple myeloma.Academic Article Why?
A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.Academic Article Why?
A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma.Academic Article Why?
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.Academic Article Why?
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.Academic Article Why?
Per Page    Page  of 79last Nextnext
Prev
Search Criteria
  • Multiple Myeloma
Filter by Type